If you are searching for a breast implant autoimmune lawsuit, the practical picture in 2026 is this: the one large-scale class settlement that ever paid autoimmune-type claims, the Dow Corning trust, finished its work and was formally terminated by court order on December 30, 2024.1Claimants’ Advisory Committee. Dow Corning Settlement Program No active class action currently exists for autoimmune or “breast implant illness” claims. Individual suits are still filed, but they run into a wall of scientific and evidentiary rulings built up over the past thirty years. The large active litigation against an implant maker today is about a rare cancer, not autoimmune disease.
Why Autoimmune Claims Became Hard to Win
Juries in the early 1990s handed down very large verdicts against implant manufacturers on the theory that silicone caused connective-tissue and autoimmune disease. That trajectory reversed once the epidemiology arrived. Starting in 1994, a series of large studies published in the New England Journal of Medicine found no increased risk of connective-tissue disease among women with silicone implants, and in 1995 the American College of Rheumatology issued a statement saying the evidence showed no demonstrable association between silicone implants and rheumatic or connective-tissue disease.2AMA Journal of Ethics. Silicone Breast Implant Litigation
Courts then closed the courtroom door on the underlying causation testimony. In December 1996, U.S. District Judge Robert E. Jones ruled in Hall v. Baxter Healthcare Corp. that the scientific evidence linking silicone implants to systemic disease was insufficient to be presented to a jury. He had appointed four independent technical advisors in immunology, epidemiology, rheumatology, and biochemistry, held a “science day” tutorial, and dismissed roughly 70 claims after excluding the plaintiffs’ expert testimony. Chief Judge Sam C. Pointer Jr., who oversaw the national multidistrict litigation (MDL-926), appointed his own Rule 706 panel; its November 1998 report also concluded the evidence did not establish a link between silicone implants and systemic connective-tissue or autoimmune diseases.3Federal Judicial Center. Court-Appointed Expert Panels in Breast Implant Litigation
The most cited assessment is the 1999 Institute of Medicine report Safety of Silicone Breast Implants, commissioned by Congress. Its 400-page review concluded that silicone gel breast implants did not cause autoimmune disease, cancer, neurological disease, or any “novel” syndrome, and that the symptoms attributed to such a syndrome were “nonspecific and common in the general population.” The report did find that local complications, rupture, capsular contracture, infection, and pain were “frequent enough to be a cause for concern.”4National Center for Biotechnology Information. Safety of Silicone Breast Implants
After Hall and the MDL-926 panel report, manufacturers began winning about 80 percent of cases brought against them, according to New York Times reporting cited in the litigation record.2AMA Journal of Ethics. Silicone Breast Implant Litigation Those rulings still shape what a plaintiff can put in front of a jury today.
The Dow Corning Settlement Is Closed
Dow Corning filed for Chapter 11 in May 1995 while facing roughly 20,000 pending suits and 410,000 potential claims.5PBS Frontline. Breast Implants Chronology6Lieff Cabraser Heimann & Bernstein. Silicone Gel Breast Implant Litigation1Claimants’ Advisory Committee. Dow Corning Settlement Program
The takeaway for anyone searching now: the Dow Corning window is closed. There is no successor class fund for autoimmune claims to file into.
Breast Implant Illness and the Current State of the Science
“Breast Implant Illness” (BII) has emerged as an umbrella term for a constellation of systemic symptoms reported by some women with implants, including chronic fatigue, joint and muscle pain, cognitive difficulties, and skin rashes. Some researchers place BII within a broader proposed category called Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA).7Taylor & Francis Online. Breast Implant Illness and ASIA Syndrome
More recent research has reopened parts of the older debate. A large retrospective study by Watad and colleagues found women with silicone implants had a 45 percent increased risk of being diagnosed with at least one autoimmune or rheumatic disorder, with the strongest associations for Sjögren’s syndrome, systemic sclerosis, and sarcoidosis. A separate cohort study of nearly 100,000 patients found elevated rates of Sjögren’s syndrome and scleroderma among implant recipients.7Taylor & Francis Online. Breast Implant Illness and ASIA Syndrome8PubMed Central. Breast Implant-Associated Immunological Disorders Studies suggest explantation resolves symptoms in 60 to 80 percent of affected patients.
A 2024 review in Cureus called the association between breast implants and connective-tissue diseases a subject of “ongoing debate,” discussing proposed mechanisms including foreign body reaction, bacterial biofilms on the implant surface, and silicone acting as an immune adjuvant.9Cureus. Connective Tissue and Autoimmune Diseases Associated With Postsurgical Breast Augmentation No official diagnostic criteria for BII exist, and routine clinical tests often come back normal. That absence of an accepted diagnostic standard is one of the practical reasons individual suits remain hard: a plaintiff needs an expert opinion tying a specific illness to a specific product, and the earlier rulings have made courts skeptical of that testimony.
What the FDA Now Requires
The FDA has tightened labeling around implants even without a settled scientific consensus. On September 29, 2020, the agency issued updated labeling guidance, and on October 27, 2021, it mandated that all legally marketed breast implants carry a black box warning, its highest level of caution. The requirements include a patient decision checklist that must be signed by both the patient and the surgeon, detailed disclosures about the chemicals and heavy metals in the devices, updated rupture screening recommendations, and a patient device card.10FDA. Breast Implants Since the October 2021 requirements, manufacturers must also alert patients to BII as a recognized risk before surgery.8PubMed Central. Breast Implant-Associated Immunological Disorders
Sales are restricted to providers and facilities that use the manufacturer-provided checklist.11Arizona Department of Health. Breast Implant Safety Requirements For someone considering a claim, the paperwork the surgeon and manufacturer collected around the surgery, including that signed checklist and device card, is now central to what a case would look like.
What Is Actively Being Litigated: Allergan BIA-ALCL
The largest active breast implant litigation is not an autoimmune case. It is about breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare cancer of the immune system linked primarily to textured breast implants. On July 24, 2019, the FDA requested that Allergan voluntarily recall its Biocell textured breast implants and tissue expanders worldwide. At the time, 573 global cases of BIA-ALCL had been recorded, with 481 involving Allergan textured implants and 33 reported deaths.12FDA. Allergan Voluntarily Recalls BIOCELL Textured Breast Implants
The cases were consolidated into MDL 2921, In re: Allergan Biocell Textured Breast Implant Products Liability Litigation, in the U.S. District Court for the District of New Jersey before Judge Brian R. Martinotti.13U.S. District Court, District of New Jersey. Allergan Biocell Textured Breast Implant Products Liability Litigation14Berger Montague. Allergan Breast Implant Lawsuit15Drugwatch. Allergan Breast Implant Lawsuits16U.S. District Court, District of New Jersey. MDL 2921 Case Management Order No. 37 In December 2025, the court formalized a Qualified Settlement Fund, though no global settlement has been announced.17Nigh Goldenberg Raso & Vaughn. Allergan Breast Implant MDL 2921 Case Management Orders
One important boundary: MDL 2921 is a cancer case, not an autoimmune case. If your concern is systemic symptoms rather than a BIA-ALCL diagnosis, this MDL is not the vehicle for your claim.
Other Manufacturers
Mentor, now a subsidiary of Johnson & Johnson (acquired for $1.1 billion in 2008), has been sued by individual plaintiffs alleging injuries from leaking silicone implants, including pain, fatigue, and skin rashes. Courts have dismissed several Mentor cases under the “learned intermediary” doctrine, ruling the manufacturer satisfied its duty by warning physicians rather than patients directly. As of late 2019, Mentor had not lost a case in court.18Breast Implant Cancer. Mentor Breast Implant Lawsuit That doctrine is a recurring problem for individual implant plaintiffs: the warning duty runs to the surgeon, and if the surgeon was warned, the manufacturer’s duty is generally treated as met.
Sientra, a smaller manufacturer whose products were made in Brazil, has faced at least one federal BIA-ALCL suit, Painter-Hart v. Sientra, filed in the Eastern District of Tennessee. The plaintiff received implants in November 2013 and was diagnosed with breast lymphoma in October 2019.19AboutLawsuits.com. Sientra Breast Implant Lawsuit Sientra filed for Chapter 11 bankruptcy in February 2024 and was acquired by Tiger Aesthetics Medical in April 2024, which changes what recovery against that company looks like going forward.20Dr. Baxter. Sientra Breast Implant Bankruptcy
Where That Leaves You
If you have autoimmune or systemic symptoms you attribute to your implants, there is no open class action to file into. The Dow Corning trust is closed, the active federal MDL is about a specific cancer tied to specific textured Allergan devices, and individual autoimmune suits face both the 1990s Daubert-era exclusions and the learned intermediary doctrine. Newer studies keep the scientific question open, and the FDA’s 2021 black box regime now formally lists BII as a risk manufacturers must disclose, but neither development has produced a settled legal pathway for autoimmune damages. A plaintiff’s lawyer working in this area is the person who can tell you whether your specific device, diagnosis, and timeline fit any current filing window.